Category: Portfolio

January 15, 2018 – Mironid is delighted to announce the appointment of Dr Enno Klussmann to our Scientific Advisory Board Dr. Klussmann is currently a

CRESTWOOD, Ky. and CAMBRIDGE, Ma., Dec. 20, 2017- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to

LOUISVILLE, Ky. and CAMBRIDGE Mass., Dec. 08, 2017 – Apellis Pharmaceuticals,Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the

Acquisition Marks Further Success for the Epidarex Portfolio Bethesda, Md., December 7, 2017 – Epidarex Capital (“Epidarex”), an early-stage, transatlantic life science venture fund, today

Bethesda, Maryland, USA, and Edinburgh, UK: Epidarex Capital (“Epidarex”), an early-stage, transatlantic life science venture fund, is pleased to announce the initial public offering (“IPO”)

Crestwood, Kentucky, Nov. 13, 2017 – Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through

Crestwood, Kentucky, Nov. 08, 2017 – Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease

Device May Improve Quality and Frequency of Repair Baltimore, Maryland – A new study has found that a pioneering device to repair heart valves is

Corporate venture fund invests EUR 4 million (USD 5 million) into Topas Financing to accelerate clinical trials in autoimmune diseases Detlev Mennerich, Ph.D., Investment Manager

Highly accomplished pharmaceutical executive with many years of clinical development, medical affairs, and regulatory experience at Bayer and Schering To lead Topas’ clinical development and